Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up

BACKGROUND: Prevalence data of chronic hepatitis C virus (HCV) infection are needed to estimate the budgetary impact of reimbursement of direct-acting antivirals (DAAs). In Belgium, the restricted reimbursement criteria are mainly guided by regional seroprevalence estimates of 0.87% from 1993 to 199...

Descripción completa

Detalles Bibliográficos
Autores principales: Litzroth, Amber, Suin, Vanessa, Wyndham-Thomas, Chloé, Quoilin, Sophie, Muyldermans, Gaëtan, Vanwolleghem, Thomas, Kabamba-Mukadi, Benoît, Verburgh, Vera, Jacques, Marjorie, Van Gucht, Steven, Hutse, Veronik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325873/
https://www.ncbi.nlm.nih.gov/pubmed/30621662
http://dx.doi.org/10.1186/s12889-018-6347-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325873/
https://www.ncbi.nlm.nih.gov/pubmed/30621662
http://dx.doi.org/10.1186/s12889-018-6347-z

Ejemplares similares